SNTI Q3'26 Earnings: revenue estimate is 0 USD

SNTI (Senti Biosciences) will report Q3'26 earnings on November 12. Analysts expect 0 USD revenue and a loss of 0.21 USD per share. Details are available on the company's financials page.

Original reporting

tradingview.com

Published Nov 5, 2026, 12:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 5, 2026, 12:07 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

SNTI Q3'26 Earnings: revenue estimate is 0 USD — source image — Source · tradingview.com

Decision brief

The 30-second read

$SNTIBearishLow

Why it matters

The zero‑revenue guidance is a stark negative signal, likely prompting immediate price decline when results are released.

Market read

The guidance is a primary earnings disclosure for a micro‑cap, offering limited but actionable insight for traders focused on biotech.

What to watch

Potential upcoming partnership or licensing deal not disclosed in the preview could offset the negative guidance.

Relevance 5/10Novelty 4/10Timing: pre‑market on November 12

Background

SNTI is a micro‑cap biotech that has not reported revenue in prior quarters; the article previews its upcoming Q3'26 earnings.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$SNTIBearishMedium confidence

Context

Article provides the Q3'26 revenue estimate of $0 and EPS of -$0.21 for SNTI ahead of its earnings release.

Expected impact

downward pressure as market prices in the disappointing guidance

Evidence & confidence

Guidance of $0 revenue is a material negative surprise for a micro‑cap biotech, prompting traders to short or reduce exposure.

Market effects

Sector

May weigh on other small‑cap biotech stocks awaiting earnings.

Regional

Limited to US biotech sector; no broader market effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

If the $0 revenue estimate reflects a temporary reporting anomaly, the stock could rebound on a surprise beat.

Key entities

Company
Senti Biosciences Holdings, Inc.
US‑listed biotech (NASDAQ: SNTI) reporting Q3'26 earnings.

Read at source ← All news

$SNTIMed

Senti Biosciences Holdings, Inc. (SNTI): Completion of Acquisition or Disposition of Assets

Senti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 SENTI BIOSCIENCES HOLDINGS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION The following unaudited pro forma condensed consolidated financial information presents the historical financial information of Senti Biosciences Holdings, Inc. (the “Co

SEC EDGAR 8-KOct 26

$SNTIMed

Senti Biosciences Holdings, Inc. (SNTI): Results of Operations and Financial Condition

Senti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-2.1 2 exhibit21-agreementandplan.htm EX-2.1 Document Exhibit 2.1 ______________________________________________ AGREEMENT AND PLAN OF MERGER BY AND AMONG CELADON PARTNERS SPV 35 LIMITED, SENTI MERGER SUB, INC., SENTI BIOSCIENCES HOLDING, INC., SENTI HOLDINGS, INC., AND SENTI B

SEC EDGAR 8-KJul 15

$JBSMed

JBS signals ~$500M 2027 capex reduction while targeting leverage below 3x by end-2027 (NYSE:JBS)

JBS N.V. (JBS) plans to reduce capital expenditures by approximately $500 million by 2027 and aims to lower its leverage ratio to below 3x by the end of 2027. The company's strategic adjustments are intended to improve its financial position.

seekingalpha.comNov 10

$GOSSMed

Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update – New Drug Application for Seralutinib in PAH Submitted to the U.S. FDA in September 2026 – – Structured Private Placement Provides $25 Million Upfront and Up to $125 Million of

SEC EDGAR 8-KNov 10

$GSLHighAI 8/10

Global Ship Lease, Inc. (GSL): Financial results for Q3 2026

Global Ship Lease, Inc. (GSL) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Investor and Media Contacts: IGB Group Bryan Degnan 646-673-9701 or Leon Berman 212-477-8438 Global Ship Lease Reports Results for the Third Quarter of 2026 Annualized dividend to increase to $2.75 per Class A Common Share Further de-risked our newbuilding program wi

SEC EDGAR 6-KNov 10

$AZTAMedAI 8/10

Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026

Azenta, Inc. (AZTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026. • Q4'26 reported revenue growth of 5% year over year and 2% on an organic basis • FY'26 reported revenue growth of 5% year over year and 2% on an organic basis • FY'27 repo